KR20080030655A - 암 치료용 항-ｃｃｒ7 수용체 항체들 - Google Patents

암 치료용 항-ｃｃｒ7 수용체 항체들 Download PDF

Info

Publication number
KR20080030655A
KR20080030655A KR1020087003130A KR20087003130A KR20080030655A KR 20080030655 A KR20080030655 A KR 20080030655A KR 1020087003130 A KR1020087003130 A KR 1020087003130A KR 20087003130 A KR20087003130 A KR 20087003130A KR 20080030655 A KR20080030655 A KR 20080030655A
Authority
KR
South Korea
Prior art keywords
cells
ccr7
antibody
antibodies
tumor cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020087003130A
Other languages
English (en)
Korean (ko)
Inventor
세실리아 무노스 칼레자
마누엘 지저스 알폰소 페레스
소니아 로페스 기랄
Original Assignee
유니버시다드 오토노마 데 마드리드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 유니버시다드 오토노마 데 마드리드 filed Critical 유니버시다드 오토노마 데 마드리드
Publication of KR20080030655A publication Critical patent/KR20080030655A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020087003130A 2005-07-06 2006-07-05 암 치료용 항-ｃｃｒ7 수용체 항체들 Ceased KR20080030655A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/EP2005/007371 WO2007003216A1 (en) 2005-07-06 2005-07-06 Anti-ccr7 receptor antibodies for the treatment of cancer
WOPCT/EP2005/007371 2005-07-06

Publications (1)

Publication Number Publication Date
KR20080030655A true KR20080030655A (ko) 2008-04-04

Family

ID=36021798

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020087003130A Ceased KR20080030655A (ko) 2005-07-06 2006-07-05 암 치료용 항-ｃｃｒ7 수용체 항체들

Country Status (16)

Country Link
US (1) US8066996B2 (enExample)
EP (1) EP1904102B1 (enExample)
JP (1) JP5249025B2 (enExample)
KR (1) KR20080030655A (enExample)
CN (1) CN101257923A (enExample)
AT (1) ATE453407T1 (enExample)
AU (1) AU2006265281C1 (enExample)
BR (1) BRPI0612632A2 (enExample)
CA (1) CA2614080C (enExample)
DE (1) DE602006011466D1 (enExample)
DK (1) DK1904102T3 (enExample)
ES (1) ES2338919T3 (enExample)
IL (1) IL188594A (enExample)
PT (1) PT1904102E (enExample)
RU (1) RU2404808C2 (enExample)
WO (2) WO2007003216A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2852549T3 (es) 2005-02-09 2021-09-13 Sarepta Therapeutics Inc Composición antisentido para tratamiento de la atrofia muscular
WO2009139853A2 (en) * 2008-05-14 2009-11-19 Kim, Eldar Human monoclonal antibodies against human chemokine receptor ccr7
US9101559B2 (en) 2009-05-08 2015-08-11 New York University Leukemic cell CNS infiltration controlled by notch-induced chemotaxis
WO2011040428A1 (ja) * 2009-09-29 2011-04-07 学校法人慶應義塾 抗腫瘍剤およびそのスクリーニング方法
JP5315495B2 (ja) * 2010-09-28 2013-10-16 積水化学工業株式会社 抗ヒトｃｃｒ７抗体、ハイブリドーマ、核酸、ベクター、細胞、医薬組成物、並びに、抗体固定化担体
US20130085139A1 (en) 2011-10-04 2013-04-04 Royal Holloway And Bedford New College Oligomers
JP6469644B2 (ja) * 2013-03-15 2019-02-13 アムジエン・インコーポレーテツド 抗ｃｃｒ７抗原結合タンパク質に関係する方法および組成物
JP6618191B2 (ja) * 2014-03-27 2019-12-11 国立研究開発法人医薬基盤・健康・栄養研究所 脳マラリアの診断および治療
MA41795A (fr) 2015-03-18 2018-01-23 Sarepta Therapeutics Inc Exclusion d'un exon induite par des composés antisens dans la myostatine
CA2994214C (en) 2015-08-10 2024-03-12 Pepmab B.V. Humanized anti-ccr7 receptor antibodies
WO2017062835A2 (en) 2015-10-09 2017-04-13 Sarepta Therapeutics, Inc. Compositions and methods for treating duchenne muscular dystrophy and related disorders
WO2018073248A1 (en) 2016-10-17 2018-04-26 Icm (Institut Du Cerveau Et De La Moelle Épinière) Prognosis of demyelinating diseases patients and treatment thereof
JOP20190187A1 (ar) * 2017-02-03 2019-08-01 Novartis Ag مترافقات عقار جسم مضاد لـ ccr7
WO2020127509A1 (en) * 2018-12-18 2020-06-25 Catapult Therapeutics B.V. The use of anti-ccr7 mabs for the prevention or treatment of graft-versus-host disease (gvhd)
US20230181756A1 (en) * 2020-04-30 2023-06-15 Novartis Ag Ccr7 antibody drug conjugates for treating cancer
CN119390838B (zh) * 2024-05-29 2025-06-10 锐胜科生物医药(上海)有限公司 一种靶向ccr7的纳米抗体及其制备与应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7163681B2 (en) * 2000-08-07 2007-01-16 Centocor, Inc. Anti-integrin antibodies, compositions, methods and uses
FR2818747B1 (fr) * 2000-12-26 2003-05-16 Molecular Engines Laboratoires Procede de criblage base sur l'interaction siah-numb
US20020168358A1 (en) * 2001-04-30 2002-11-14 Gladue Ronald P. Treatment of T-cell mediated diseases
DE10248751A1 (de) * 2002-10-18 2004-05-06 Berdel, Wolfgang E., Prof. Dr.med. Dyslokalisationsmoleküle und deren Verwendung
WO2004104574A2 (en) * 2003-05-23 2004-12-02 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with c-c chemokine receptor type 7 (ccr7)
AU2004253465A1 (en) * 2003-06-11 2005-01-13 The University Of Chicago Increased T-cell tumor infiltration by mutant light

Also Published As

Publication number Publication date
BRPI0612632A2 (pt) 2012-01-03
DK1904102T3 (da) 2010-04-19
EP1904102A1 (en) 2008-04-02
AU2006265281B2 (en) 2012-03-01
CA2614080C (en) 2014-08-26
CA2614080A1 (en) 2007-01-11
RU2404808C2 (ru) 2010-11-27
AU2006265281A1 (en) 2007-01-11
DE602006011466D1 (de) 2010-02-11
CN101257923A (zh) 2008-09-03
ES2338919T3 (es) 2010-05-13
JP5249025B2 (ja) 2013-07-31
RU2008104420A (ru) 2009-08-20
AU2006265281C1 (en) 2012-11-15
US20090123483A1 (en) 2009-05-14
IL188594A (en) 2012-02-29
WO2007003216A1 (en) 2007-01-11
ATE453407T1 (de) 2010-01-15
US8066996B2 (en) 2011-11-29
WO2007003426A1 (en) 2007-01-11
PT1904102E (pt) 2010-03-29
IL188594A0 (en) 2008-04-13
EP1904102B1 (en) 2009-12-30
JP2008545000A (ja) 2008-12-11

Similar Documents

Publication Publication Date Title
ES2550621T3 (es) Anticuerpos anti-CD19 y usos en oncología
IL188594A (en) Anti-ccr7 receptor antibodies for the treatment of cancer
KR101363780B1 (ko) 항-ανβ6 항체 및 이의 용도
RU2520088C2 (ru) Антитела к ох-2/сd200 и их применение
CN109069620B (zh) 拮抗剂ccr7受体的人源化抗体
KR102338832B1 (ko) Ccr9에 대한 항체 및 그의 적용방법
JP6268237B2 (ja) 癌療法のためのａｂｃｂ５標的化
EP2032166A2 (en) Compositions and methods for diagnosing and treating cancer
CN1981868A (zh) 抗细胞因子抗体或拮抗剂与抗－cd20在b细胞淋巴瘤治疗中的联合应用
AU2002236519A1 (en) Methods for the prevention and treatment of cancer using anti-C3B(i) antibodies
CN101547936A (zh) 癌性疾病调节抗体
HK1124760A (en) Anti-ccr7 receptor antibodies for the treatment of cancer

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20080205

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20110704

Comment text: Request for Examination of Application

PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20130410

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20130716

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20130410

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I